MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]
Drug-Device Combinations
MiniMed Flex now integrated with Abbot’s Instinct sensor
MiniMed (Nasdaq: MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. The MiniMed Flex system is MiniMed’s smallest and only app-controlled insulin pump. According to the company, Instinct is the world’s smallest sensor and offers up to 15 days of wear. Powered by SmartGuard technology, MiniMed Flex automatically adjusts insulin delivery, and the Meal Detection technology can […]
Embecta Q3 results beat analyst expectations
Julia Rock-Torcivia Embecta Corp. (Nasdaq: EMBC) raised its full-year outlook for adjusted earnings per share as third-quarter results beat analyst estimates. The medtech company, a BD spinoff that specializes in insulin delivery, reported last week net income of $21.1 million, or $0.36 per share, on revenue of $271.7 million for the three months ended June […]
ICU Medical Q2 results beat analyst expectations, driven by infusion systems
Julia Rock-Torcivia ICU Medical (Nasdaq: ICUI) reported second quarter results that beat Wall Street expectations, upping its full-year guidance. San Clemente, California–based ICE Medical, which specializes in IV therapy, infusion pumps and closed-system drug transfer devices, reported income of $19.1 million, or 76¢ per share, on revenue of $551.7 million for the three months ended June […]
6 diabetes tech companies you need to know
You may already know a lot of the names that are considered leaders of the diabetes technology industry. The likes of Abbott and Dexcom are leaders in the continuous glucose monitor (CGM) space. MiniMed, Insulet and Tandem Diabetes Care are a few of the companies with a significant share in the automated insulin delivery (AID) […]
The 10 largest diabetes tech companies in the world in 2026
Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
Insulet slightly lowers 2026 sales growth outlook despite Q2 beats
Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth […]
Modular Medical to initiate first phase of Pivot pump launch in October
Modular Medical (Nasdaq:MODD) announced its plans to initiate the first phase of the launch of its Pivot tubeless insulin patch pump. Pivot, designed to make insulin pump therapy simpler to learn and easier to live with, features a removable, two-part design and a 3 mL reservoir, intuitive interface and flexible, wearable form factor. The system […]
GLP-1 therapies delivered by Stevanato Group pen injectors get green light in Europe
Stevanato Group announced today that liraglutide products incorporating its Alina pen injector received marketing authorization in Europe. Approved liraglutide-based combination products include Alina 30, developed for these therapies for diabetes, as well as Alina 50 for weight management applications. Both variants come as part of the company’s broader Alina variable-dose pen injector platform. The platform […]
